(NASDAQ: ALT) Altimmune's forecast annual revenue growth rate of 313.34% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.06%.
Altimmune's revenue in 2024 is $426,000.On average, 1 Wall Street analysts forecast ALT's revenue for 2024 to be $17,723,821,500, with the lowest ALT revenue forecast at $17,723,821,500, and the highest ALT revenue forecast at $17,723,821,500. On average, 1 Wall Street analysts forecast ALT's revenue for 2025 to be $14,179,057,200, with the lowest ALT revenue forecast at $14,179,057,200, and the highest ALT revenue forecast at $14,179,057,200.
In 2026, ALT is forecast to generate $432,461,245 in revenue, with the lowest revenue forecast at $432,461,245 and the highest revenue forecast at $432,461,245.